WHC is still in active development. Read this to understand our approach.
depiction of ZAFYATHCZYHLPB-UHFFFAOYSA-N.svg
tripsit

zolpidem

Check on tripsit

psychonaut

Zolpidem

Check on psychonaut

isomerdesign

Zolpidem

Check on isomerdesign

druglab

Zolpidem

Check on druglab

drugmap

Zolpidem

Check on drugmap

drugmap

Zolpidem

Check on drugmap

Data

InChI: InChI=1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3

Synonyms: SR-01000763006-3,DTXSID7045946, ZAFYATHCZYHLPB-UHFFFAOYSA-N,zolpidem,Z-100, NCGC00095179-01, [3H]zolpidem,Sanval,N,N,6-TRIMETHYL-2-P-TOLYL-IMIDAZO(1,2-A)PYRIDINE-3-ACETAMIDE,N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide #,7K383OQI23, Lorex,ambien,CS-1468,BCP10205,UNII-7K383OQI23,N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide.,HY-17441, Zolpidem [INN:BAN],N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide, Ancer 20,Ancer, Zolpidemum [Latin],AKOS005560130,Zolpidem civ, Specific Substance of Maruyama,Zolpidem, >=98% (HPLC), solid,Zolpidem solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,Zolpidemum,Zolpidem [INN:BAN],CHEMBL911,NCGC00095179-03,STK627113,SL-800750,ZOLPIDEM [VANDF],SL800750, Ambien,NCGC00095179-05,HMS1922F22,DSSTox_GSID_45946,SL 800750; SL-800750; SL800750,SL 80-0750, N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide, Zolpidemum, N,N,6-Trimethyl-2-p-tolylimidazo[1,2-a]pyridine-3-acetamide,GTPL4362, DEA No 2783,NCGC00095179-02,AB00698471_09,AS-35386,BSPBio_002278,Tox21_111471_1,NCGC00095179-01, UNII-7K383OQI23,BDBM26266,D08690,CAS-82626-48-0,BRD-K44876623-001-01-1,N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide,DB00425,[3H]zolpidem,294Z936,Zolpidem D6,N,N-dimethyl-2-[(4S)-6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide,Zolpidemum [Latin],82626-48-0,Sanval (TN),SL 800750, N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide,Tox21_111471,ZINC3876, N,N,6-Trimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide,SR-01000763006,NCGC00095179-04, SL-800750,N,N-Dimethyl-2-[3-methyl-8-(4-methylphenyl)-1,7-diazabicyclo[4.3.0]nona-2,4,6,8-tetraen-9-yl]- acetamide,DTXCID5025946,stilnox,ZOLPIDEM [INN],zolpidem Ambien,ZOLPIDEM [MI],ZOLPIDEM [WHO-DD],BIDD:GT0785, ZolpiMist,6-methyl-N,N-dimethyl-2-(4-methylphenyl)imidazo[1,2-a]pyridine-3-acetamide,Q218842,Zolpidem,GTPL4348,ZOLPIDEM CIV [USP-RS], CHEMBL911,N,N,6-Trimethyl-2-(4-Methyl Phenyl) Imidazo [1,2-alpha] Pyridine-3-Acetamide,DSSTox_CID_25946,SPECTRUM1505369,DSSTox_RID_81244, Zolpidem (low-dose oral spray, middle-of-the-night awakenings),SCHEMBL80516,Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-,C07219,CCG-213403,N,N,6-Trimethyl-2-(4-methylphenyl)imidazo(1,2-a)pyridine-3-acetamide,N,N-Dimethyl-2-(6-methyl-2-p-tolyl-imidazo[1,2-a]pyridin-3-yl)-acetamide,Zolpidem (INN),CHEBI:10125, 7K383OQI23,N,N-Dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[1,2-a]pyridin-3-yl]acetamide, CHEBI:10125, 82626-48-0, SSM, Zolpidem tartrate, Zolpidem (low-dose oral spray, middle-of-the-night awakenings), NovaDel,N,N-dimethyl-2-[6-methyl-2-(4-methylphenyl)imidazo[3,2-a]pyridin-3-yl]acetamide,AB00698471-07

Estimated data

Solubility: -4.349 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: No (prediction using frontiersin.org)

Addictivity Prediction: 63.2% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.